MARINOMED BIOTECH AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.65 EUR | -6.46% |
|
-12.37% | -42.98% |
| 16/04 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
| 16/04 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 147 | 175.2 | 130.3 | 84.95 | 44.36 | 27.42 | - | - |
| Enterprise Value (EV) 1 | 139.6 | 178.9 | 140.3 | 96.95 | 44.36 | 27.42 | 27.42 | 27.42 |
| P/E ratio | -19.6 x | -29 x | -22 x | -13.1 x | -6.49 x | 57.4 x | 13.6 x | 10.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.9 x | 21.6 x | 11.2 x | 7.53 x | 4.83 x | 1.51 x | 1.17 x | 0.91 x |
| EV / Revenue | 23.9 x | 21.6 x | 11.2 x | 7.53 x | 4.83 x | 1.51 x | 1.17 x | 0.91 x |
| EV / EBITDA | -25 x | -32.5 x | -37.2 x | -20 x | -9.97 x | 13.3 x | 4.73 x | 3.04 x |
| EV / FCF | - | -16.2 x | - | -15.6 x | -9.53 x | 3.26 x | 1.97 x | 2.52 x |
| FCF Yield | - | -6.19% | - | -6.39% | -10.5% | 30.6% | 50.7% | 39.7% |
| Price to Book | - | 32.7 x | 681 x | -20.4 x | -4.39 x | -5.93 x | - | - |
| Nbr of stocks (in thousands) | 1,470 | 1,473 | 1,480 | 1,506 | 1,519 | 1,541 | - | - |
| Reference price 2 | 100.0 | 119.0 | 88.00 | 56.40 | 29.20 | 17.80 | 17.80 | 17.80 |
| Announcement Date | 16/04/20 | 14/04/21 | 13/04/22 | 19/04/23 | 16/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.145 | 8.124 | 11.6 | 11.28 | 9.184 | 18.19 | 23.47 | 30.27 |
| EBITDA 1 | -5.883 | -5.388 | -3.5 | -4.244 | -4.451 | 2.06 | 5.8 | 9.01 |
| EBIT 1 | -6.21 | -5.816 | -4.1 | -4.914 | -5.129 | 1.05 | 4.47 | 7.32 |
| Operating Margin | -101.07% | -71.59% | -35.34% | -43.58% | -55.85% | 5.77% | 19.05% | 24.18% |
| Earnings before Tax (EBT) 1 | -7.212 | -6.007 | -5.7 | -6.391 | -6.791 | 0.51 | 2.34 | 3.24 |
| Net income 1 | -7.216 | -6.01 | -5.9 | -6.398 | -6.795 | 0.47 | 1.98 | 2.59 |
| Net margin | -117.44% | -73.98% | -50.86% | -56.74% | -73.99% | 2.58% | 8.44% | 8.56% |
| EPS 2 | -5.100 | -4.100 | -4.000 | -4.300 | -4.500 | 0.3100 | 1.310 | 1.710 |
| Free Cash Flow 1 | - | -10.85 | - | -5.43 | -4.657 | 8.4 | 13.9 | 10.9 |
| FCF margin | - | -133.53% | - | -48.16% | -50.71% | 46.18% | 59.22% | 36.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 407.77% | 239.66% | 120.98% |
| FCF Conversion (Net income) | - | - | - | - | - | 1,787.23% | 702.02% | 420.85% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 16/04/20 | 14/04/21 | 13/04/22 | 19/04/23 | 16/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 3.61 | 10 | 12 | - | - | - | - |
| Net Cash position | 7.38 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.6695 x | -2.857 x | -2.829 x | - | - | - | - |
| Free Cash Flow 1 | - | -10.8 | - | -5.43 | -4.66 | 8.4 | 13.9 | 10.9 |
| ROE (net income / shareholders' equity) | - | -74.1% | -211% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 3.640 | 0.1300 | -2.760 | -6.650 | -3.000 | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.34 | 3.96 | - | 0.23 | 0.13 | 6.08 | 3.7 | 4.7 |
| Capex / Sales | 38.1% | 48.79% | - | 2.02% | 1.4% | 33.42% | 15.76% | 15.53% |
| Announcement Date | 16/04/20 | 14/04/21 | 13/04/22 | 19/04/23 | 16/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
17.8
EUR
Average target price
63
EUR
Spread / Average Target
+253.93%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.98% | 29.38M | |
| -3.45% | 87.17B | |
| +1.97% | 40.1B | |
| +57.41% | 25.12B | |
| -14.82% | 15.59B | |
| -8.82% | 12B | |
| -16.29% | 11.8B | |
| -41.58% | 11.8B | |
| +7.64% | 8.81B | |
| -10.53% | 8.24B |
- Stock Market
- Equities
- MARI Stock
- Financials Marinomed Biotech AG
